

The organisers wish to thank GlaxoSmithKline and AstraZeneca for their sponsorship of this meeting and the NMRDG for their help and support with the organisation.



NMRDG Spring Meeting

**Advances in NMR on Small
Amounts of Material**

Thursday 26th Feb 2004

AstraZeneca R&D Charnwood, Loughborough, UK

9.45 Coffee

10.20 Introduction and Welcome (Mike Bernstein, AstraZeneca)

Session 1 Introduction to the Techniques

Chair: Richard Lewis (AstraZeneca)

10.30 Steve Coombes (Pfizer, Sandwich)
Cryo-flow probes: Fixed and demountable flow cells

10.45 Martin Sandvoss (GSK)
LC-SPE-NMR, separating the chromatography from the NMR

11.00 Dave Russell (Pfizer, Kalamazoo)
Optimising one's sample for cryogenic NMR probes

11.15 Ian Jones (AstraZeneca R&D Macclesfield)
Experience with the 1mm probe in a pharmaceutical development environment

11.30 Chris Sleight (AstraZeneca R&D Charnwood)
Evaluation of a CapNMR and CapLCNMR system

11.45 Paul Tan (Lilly)
Automated sample preparation of small batches of compound

Buffet Lunch

Session 2 A Glimpse of the Future

Chair: Martin Sandvoss (GSK)

1.00 Klaus Albert (Institut für Organische Chemie, Universität Tübingen, Germany)
LC-NMR – Present status and future

- 1.30 David Strand (Protasis)
Dynamic Field Gradient Focusing: A new separation engine for NMR
- 1.45 Manfred Spraul (Bruker)
Methods to increase NMR performance on small sample amounts
- 2.00 Iain Green (Varian Inc)
Small molecules, small samples, big applications, a vendor perspective
- 2.15 Peter Meadows (Jeol)
Who says NMR is Insensitive?

2.30 Coffee

Session 3 Industry Workflow

How can we make these technologies work in a high-throughput environment?

Chair: Adrian Davis (Pfizer)

- 3.00 Mark O'Neil-Johnson, (Sequoia Sciences Inc., San Diego, CA)
From HPLC to NMR structure elucidation, What can I do with twenty five micrograms?
- 3.25 Russell Mortishire-Smith (Merck Sharp and Dohme)
Fish or cut bait? Workflow and metabolite identification by NMR
- 3.50 Gary Sharman (AstraZeneca R&D Macclesfield)
Impurity and degradation product identification in pharmaceutical development

4.15 Discussion

Chair: Duncan Farrant (GSK)

4.45 Closing Remarks

Followed by informal discussion.